Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
EAST RUTHERFORD, N.J., Oct. 12, 2017 -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has made a number of investments, in both R&D and manufacturing capabilities to support the development and production of generic APIs, at its site in Paullo, Milan, Italy.
The investments include the installation of development and analytical equipment to support the development of highly potent APIs (HPAPIs), as well as a new 2,800 liter hydrogenator and 1,500mm diameter centrifuge, for increased flexibility and capacity within the manufacturing plant. All equipment will be installed and validated by the end of 2017.
“We have seen increased growth of activity among highly potent molecules in the past decade for use in therapeutics for cancer and other indications, and it is now becoming more appropriate in the generic API business as patents on these begin to expire,” commented Aldo Magnini, Managing Director, Cambrex Milan. “This investment is consistent with the Cambrex strategic plan to increase the company’s small molecule development and manufacturing capabilities, ensuring our facilities continue to meet the future demands of the industry.”
This investment comes after the installation of a new pilot plant at the site in 2017, and recent announcements of expansions across the Cambrex network of manufacturing sites, including the construction of a $24M, 4,500 sq. ft. highly potent API manufacturing facility at its Charles City, Iowa site, which is due to open in 2019.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com
Contact:
Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155
Email: [email protected]
